Sucralfate: A Help During Oral Management in Patients With Epidermolysis Bullosa

Marini, Irmo; Vecchiet, Federico

doi:10.1902/jop.2001.72.5.691

Cited by 37 publications

(23 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The sporadic studies and case reports available in the literature were all coherent indicating the favorable effect of topical sucralfate in wound repair and in skin protection. Topical sucralfate has been successfully studied in peristomal and perineal dermatoses, in moist desquamation during radiotherapy, in erosion and ulceration of the perineal area, in vaginal ulceration, in dystrophic epidermolysis bullosa, in second and third degree burns, and in a pilot trial with non-healing, full-thickness venous stasis ulcers refractory to 8 weeks of conventional therapy (19)(20)(21)(22)(23)(24)(25)(26)(27). The main objective of this study was to determine the effectiveness, safety and tolerability of the local treatment of chronic wounds with a sucralfate gel (SUC-LIS 95).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Topical treatment of chronic venous ulcers with sucralfate: A placebo controlled randomized study

Tumino¹,

Masuelli²,

Bei³

et al. 2008

Int J Mol Med

View full text Add to dashboard Cite

Abstract. Venous leg ulcers are an important medical issue due to their high incidence in the elderly and the lack of a standard curative approach. Apart from surgical therapy, different medical treatments to effect ulcer wound repair and regeneration are currently being investigated. Sucralfate is a cytoprotective agent employed to prevent or treat several gastrointestinal diseases such as gastroesophageal reflux, gastritis, peptic ulcer, stress ulcer and dyspepsia. In this study we evaluated the efficacy, safety and tolerability of topical sucralfate (SUC-LIS 95) on the healing of chronic venous leg ulcers in 50 patients by a double-blind, placebo-controlled, randomized study. Our results indicated that the daily application of SUC-LIS 95 to non-infected post-phlebitis/vascular ulcers, for a median period of 42.0 days, led to complete healing in 95.6% of patients, against only 10.9% of cases with a matched placebo. A significant improvement was obtained in the SUC-LIS 95-treated patient group with regard to local tissue inflammation as well as pain and burning, and consequently, in ulcer size and the evolution of granulation tissue. Our findings were corroborated for selected patients by the morphological analysis of biopsies obtained before and after treatment. Using ultrastructural analysis we demonstrated that the topical use of SUC-LIS 95 was able to affect neoangiogenesis, increase wound contraction, promote re-epithelialization of the wound area and diminish the inflammatory reaction. Overall, our results indicated that patients with chronic venous ulcers show improvement after the use of topical sucralfate.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The sporadic studies and case reports available in the literature are all consistent, indicating the favorable effect of topical sucralfate in wound repair and in skin protection. Almost all studies indicated the safe and effective behaviour of this compound (19)(20)(21)(22)(23)(24)(25)(26)(27).…”

Section: Introductionmentioning

confidence: 99%

Topical treatment of chronic venous ulcers with sucralfate: A placebo controlled randomized study

Tumino¹,

Masuelli²,

Bei³

et al. 2008

Int J Mol Med

View full text Add to dashboard Cite

show abstract

“…Extraction of teeth was previously considered the mainstay of treatment (16) but today prevention of dental disease is the main aim with dentists working closely as part of a multidisciplinary approach (17). Oral pain can be minimised by rinsing the mouth with coating products such as sucralfate or with the use of topical anaesthetics (18).…”

Section: Current Management: Symptoms and Complicationsmentioning

confidence: 99%

Novel and emerging therapies in the treatment of recessive dystrophic epidermolysis bullosa

Rashidghamat

McGrath

2017

IRDR

View full text Add to dashboard Cite

“…A visszahívás javasolt időpontja egyén-től függően három-hat hónap, ennek kiemelt jelentősége az esetleg kezdődő rosszindulatú elváltozások korai diagnosztizálásában van. A különböző hólyagok, bullák, eróziók kialakulását, illetve fennállásuk időtartamát csök-kentheti a szukralfátszuszpenzió orális alkalmazása [20].…”

Section: Fogorvosi Vonatkozások Teendőkunclassified

Az epidermolysis bullosa szájüregi tünetei és annak ellátása

Barna

Eördegh

Iván³

et al. 2017

Orvosi Hetilap

View full text Add to dashboard Cite

Jelen összefoglaló mű célja, hogy útmutatót adjon az epidermolysis bullosa mindennapi ellátásában, a betegek orális egészségének és ezen keresztül életminőségük színvonalának emelésében, valamint támogassa a magyar általános orvosok, bőrgyógyászok és a fogorvosok közötti kooperációt. A nemzetközi irodalom alapján segítséget szeretnénk nyújtani abban, hogy a beteget gondozó bőrgyógyász vagy a háziorvos mikor vonjon be szájüreggel foglalkozó szakembert, illetve a fogorvosnak, hogy milyen fő prevenciós vagy azon túlmutató teendői vannak. A fogorvosi kezelés különböző aspektusain keresztül bemutatjuk, hogy egy fogorvos milyen módon láthatja el a pácienseket további sebek vagy fájdalom okozása nélkül, valamint milyen beavatkozásokat és hogyan tud számukra megvalósítani. Orv Hetil. 2017; 158(40): 1577-1583. Kulcsszavak: epidermolysis bullosa, fogászat, orális egészség, útmutató, terápia Epidermolysis bullosa: oral manifestations and their treatmentsThe aim of this comprehensive article is to provide guidelines for the daily treatment of patients with epidermolysis bullosa, thus contributing to the attainment of their higher quality of life through the improvement of their oral health. Moreover, it is our intention to facilitate the cooperation among Hungarian general practitioners, dermatologists and dentists. Relying on recent research findings of the international literature, we intend to help general practitioners or dermatologists treating epidermolysis bullosa patients on a daily basis by identifying symptoms that require consulting an oral professional on the one hand, and to present the most important prevention strategies and further treatments advised for dentists on the other. Focusing on various aspects of dental treatment, we specify how a dentist can treat the patient without causing additional wounds or pain, and what kinds of therapy are justified by this approach. Rövidítések DDEB = domináns dystrophiás epidermolysis bullosa; DEB = dystrophiás epidermolysis bullosa; DMF = (decayed, missing, filled) szuvas, hiányzó, tömött; EB = epidermolysis bullosa; EBS = epidermolysis bullosa simplex; IgA = immunglobulin-A; JEB = junctionalis epidermolysis bullosa; RDEB = recesszív dys trophiás epidermolysis bullosa Az epidermolysis bullosa (EB) ritka örökletes bőrbeteg-ség, amely a bőrön és nyálkahártyafelszíneken akár kisebb mechanikai behatásra is hólyagképződéshez vezethet. A hámban, illetve a hám-kötőszöveti határon, a basalis membrán zónaterületén alakul ki szétválás a struktúrfehérjék defektusa, esetleg teljes hiánya miatt.

show abstract

Sucralfate: A Help During Oral Management in Patients With Epidermolysis Bullosa

Abstract: Oral prophylaxis with sucralfate prevented oral blisters and oral discomfort. The procedure proved to be cost effective and easy to administer. It did not show significant side effects and may be used routinely in patients with EB.

Cited by 37 publications

References 28 publications

Topical treatment of chronic venous ulcers with sucralfate: A placebo controlled randomized study

Topical treatment of chronic venous ulcers with sucralfate: A placebo controlled randomized study

Novel and emerging therapies in the treatment of recessive dystrophic epidermolysis bullosa

Az epidermolysis bullosa szájüregi tünetei és annak ellátása

Contact Info

Product

Resources

About